Silencing of parathyroid hormone (PTH) receptor 1 in T cells blunts the bone anabolic activity of PTH

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 12, 2012, Pages

  Bedi, Brahmchetna ^a,b   Li, Jau Yi ^a   Tawfeek, Hesham ^a   Baek, Ki Hyun ^a   Adams, Jonathan ^a   Vangara, Sameera S ^a   Chang, Ming Kang ^c   Kneissel, Michaela ^c   Weitzmann, M Neale ^a,b   Pacifici, Roberto ^a,d  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d EMORY UNIVERSITY   (United States)

Author keywords

Bone cells; Bone mass; T lymphocytes

Indexed keywords

PARATHYROID HORMONE; PARATHYROID HORMONE RECEPTOR 1; WNT PROTEIN; WNT10B PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE DEVELOPMENT; BONE MASS; BONE TURNOVER; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE SILENCING; MORPHOMETRICS; MOUSE; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TRABECULAR BONE;

ANIMALS; BONE AND BONES; BONE DENSITY; FEMALE; GENE SILENCING; LIGANDS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MODELS, BIOLOGICAL; OSTEOBLASTS; PARATHYROID HORMONE; PROTO-ONCOGENE PROTEINS; RECEPTOR, PARATHYROID HORMONE, TYPE 1; SIGNAL TRANSDUCTION; WNT PROTEINS; X-RAY MICROTOMOGRAPHY;

EID: 84863345866     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1120735109     Document Type: Article

References (58)

1. Qin L, Raggatt LJ, Partridge NC (2004) Parathyroid hormone: A double-edged sword for bone metabolism. Trends Endocrinol Metab 15:60-65. (Pubitemid 38253007)
2. Zaidi M (2007) Skeletal remodeling in health and disease. Nat Med 13:791-801.
3. Neer RM, et al. (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441. (Pubitemid 32402100)
4. Calvi LM, et al. (2001) Activated parathyroid hormone/parathyroid hormone-related protein receptor in osteoblastic cells differentially affects cortical and trabecular bone. J Clin Invest 107:277-286. (Pubitemid 32157960)
5. Lanske B, et al. (1999) Ablation of the PTHrP gene or the PTH/PTHrP receptor gene leads to distinct abnormalities in bone development. J Clin Invest 104:399-407. (Pubitemid 29534324)
6. Lindsay R, et al. (2006) A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: Early actions of teriparatide. J Bone Miner Res 21:366-373.
7. Ma YL, et al. (2006) Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis. J Bone Miner Res 21:855-864. (Pubitemid 43787992)
8. Dobnig H, Turner RT (1997) The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology 138:4607-4612. (Pubitemid 27460894)
9. Dobnig H, Turner RT (1995) Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology 136:3632-3638.
10. Nishida S, et al. (1994) Increased bone formation by intermittent parathyroid hormone administration is due to the stimulation of proliferation and differentiation of osteoprogenitor cells in bone marrow. Bone 15:717-723. (Pubitemid 24332666)
11. Pettway GJ, et al. (2008) Parathyroid hormone mediates bone growth through the regulation of osteoblast proliferation and differentiation. Bone 42:806-818.
12. Meng XW, et al. (1996) Temporal expression of the anabolic action of PTH in cancellous bone of ovariectomized rats. J Bone Miner Res 11:421-429. (Pubitemid 26109062)
13. Schmidt IU, Dobnig H, Turner RT (1995) Intermittent parathyroid hormone treatment increases osteoblast number, steady state messenger ribonucleic acid levels for osteocalcin, and bone formation in tibial metaphysis of hypophysectomized female rats. Endocrinology 136:5127-5134.
14. Jilka RL, et al. (1999) Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 104:439-446. (Pubitemid 29534328)
15. Bellido T, et al. (2003) Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem 278:50259-50272. (Pubitemid 37548867)
16. Almeida M, Han L, Bellido T, Manolagas SC, Kousteni S (2005) Wnt proteins prevent apoptosis of both uncommitted osteoblast progenitors and differentiated osteoblasts by beta-catenin-dependent and -independent signaling cascades involving Src/ERK and phosphatidylinositol 3-kinase/AKT. J Biol Chem 280:41342-41351. (Pubitemid 41832191)
17. Tobimatsu T, et al. (2006) Parathyroid hormone increases beta-catenin levels through Smad3 in mouse osteoblastic cells. Endocrinology 147:2583-2590.
18. O'Brien CA, et al. (2008) Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS ONE 3:e2942.
19. Wu X, et al. (2010) Inhibition of Sca-1-positive skeletal stem cell recruitment by alendronate blunts the anabolic effects of parathyroid hormone on bone remodeling. Cell Stem Cell 7:571-580.
20. Tang Y, et al. (2009) TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med 15:757-765.
21. Bikle DD, et al. (2002) Insulin-like growth factor I is required for the anabolic actions of parathyroid hormone on mouse bone. J Bone Miner Res 17:1570-1578.
22. Yamaguchi M, et al. (2005) Insulin receptor substrate-1 is required for bone anabolic function of parathyroid hormone in mice. Endocrinology 146:2620-2628. (Pubitemid 40695564)
23. Jilka RL (2007) Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 40:1434-1446.
24. Kato M, et al. (2002) Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol 157:303-314. (Pubitemid 34839826)
25. Bodine PV, Komm BS (2006) Wnt signaling and osteoblastogenesis. Rev Endocr Metab Disord 7:33-39. (Pubitemid 46049520)
26. Bodine PV, et al. (2005) The Wnt antagonist secreted frizzled-related protein-1 controls osteoblast and osteocyte apoptosis. J Cell Biochem 96:1212-1230. (Pubitemid 41681864)
27. Glass DA, 2nd, et al. (2005) Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 8:751-764.
28. Wan M, et al. (2008) Parathyroid hormone signaling through low-density lipoprotein-related protein 6. Genes Dev 22:2968-2979.
29. Li X, et al. (2007) Determination of dual effects of parathyroid hormone on skeletal gene expression in vivo by microarray and network analysis. J Biol Chem 282:33086-33097. (Pubitemid 350159330)
30. Terauchi M, et al. (2009) T lymphocytes amplify the anabolic activity of parathyroid hormone through Wnt10b signaling. Cell Metab 10:229-240.
31. Keller H, Kneissel M (2005) SOST is a target gene for PTH in bone. Bone 37:148-158. (Pubitemid 40962421)
32. Bellido T, et al. (2005) Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: A novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 146:4577-4583. (Pubitemid 41446595)
33. Silvestrini G, et al. (2007) Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone. J Mol Histol 38:261-269. (Pubitemid 47106897)
34. Guo J, et al. (2010) Suppression of Wnt signaling by Dkk1 attenuates PTH-mediated stromal cell response and new bone formation. Cell Metab 11:161-171.
35. Kulkarni NH, et al. (2005) Effects of parathyroid hormone on Wnt signaling pathway in bone. J Cell Biochem 95:1178-1190. (Pubitemid 41420125)
36. Gao Y, et al. (2008) T cells potentiate PTH-induced cortical bone loss through CD40L signaling. Cell Metab 8:132-145.
37. Tawfeek H, et al. (2010) Disruption of PTH receptor 1 in T cells protects against PTH-induced bone loss. PLoS ONE 5:e12290.
38. Uccelli A, Moretta L, Pistoia V (2008) Mesenchymal stem cells in health and disease. Nat Rev Immunol 8:726-736.
39. Sato K, et al. (2007) Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 109:228-234. (Pubitemid 46053063)
40. Ahuja SS, et al. (2003) CD40 ligand blocks apoptosis induced by tumor necrosis factor alpha, glucocorticoids, and etoposide in osteoblasts and the osteocyte-like cell line murine long bone osteocyte-Y4. Endocrinology 144:1761-1769. (Pubitemid 36543313)
41. Vaes BL, et al. (2005) Microarray analysis reveals expression regulation of Wnt antagonists in differentiating osteoblasts. Bone 36:803-811. (Pubitemid 40616015)
42. Jackson A, et al. (2005) Gene array analysis of Wnt-regulated genes in C3H10T1/2 cells. Bone 36:585-598. (Pubitemid 40602252)
43. Rawadi G, Vayssière B, Dunn F, Baron R, Roman-Roman S (2003) BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop. J Bone Miner Res 18:1842-1853. (Pubitemid 37322562)
44. Luo Q, et al. (2004) Connective tissue growth factor (CTGF) is regulated by Wnt and bone morphogenetic proteins signaling in osteoblast differentiation of mesenchymal stem cells. J Biol Chem 279:55958-55968. (Pubitemid 40066603)
45. Eichinger A, et al. (2002) Transcript expression of the tuberoinfundibular peptide (TIP) 39/PTH2 receptor system and non-PTH1 receptor-mediated tonic effects of TIP39 and other PTH2 receptor ligands in renal vessels. Endocrinology 143:3036-3043. (Pubitemid 34809877)
46. Hoare SR, Clark JA, Usdin TB (2000) Molecular determinants of tuberoinfundibular peptide of 39 residues (TIP39) selectivity for the parathyroid hormone-2 (PTH2) receptor. N-terminal truncation of TIP39 reverses PTH2 receptor/PTH1 receptor binding selectivity. J Biol Chem 275:27274-27283.
47. Usdin TB, Hoare SR, Wang T, Mezey E, Kowalak JA (1999) TIP39: A new neuropeptide and PTH2-receptor agonist from hypothalamus. Nat Neurosci 2:941-943. (Pubitemid 30599554)
48. Divieti P, Geller AI, Suliman G, Jüppner H, Bringhurst FR (2005) Receptors specific for the carboxyl-terminal region of parathyroid hormone on bone-derived cells: Determinants of ligand binding and bioactivity. Endocrinology 146:1863-1870. (Pubitemid 40396896)
49. Moon RT, Bowerman B, Boutros M, Perrimon N (2002) The promise and perils of Wnt signaling through beta-catenin. Science 296:1644-1646. (Pubitemid 34579151)
50. Kimble RB, Srivastava S, Ross FP, Matayoshi A, Pacifici R (1996) Estrogen deficiency increases the ability of stromal cells to support murine osteoclastogenesis via an interleukin-1and tumor necrosis factor-mediated stimulation of macrophage colony-stimulating factor production. J Biol Chem 271:28890-28897. (Pubitemid 26382589)
51. Srivastava S, et al. (1998) Estrogen blocks M-CSF gene expression and osteoclast formation by regulating phosphorylation of Egr-1 and its interaction with Sp-1. J Clin Invest 102:1850-1859. (Pubitemid 28533832)
52. Ma YL, et al. (2001) Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology 142:4047-4054. (Pubitemid 32802678)
53. Spencer GJ, Utting JC, Etheridge SL, Arnett TR, Genever PG (2006) Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro. J Cell Sci 119:1283-1296.
54. Iida-Klein A, et al. (2002) Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice. J Bone Miner Res 17:808-816. (Pubitemid 34441897)
55. Bennett CN, et al. (2005) Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci USA 102:3324-3329. (Pubitemid 40328044)
56. Cenci S, et al. (2003) Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFN-gamma-induced class II transactivator. Proc Natl Acad Sci USA 100:10405-10410. (Pubitemid 37071891)
57. Parfitt AM, et al.; Report of the ASBMR Histomorphometry Nomenclature Committee (1987) Bone histomorphometry: Standardization of nomenclature, symbols, and units. J Bone Miner Res 2:595-610.
58. Li JY, et al. (2011) Ovariectomy disregulates osteoblast and osteoclast formation through the T-cell receptor CD40 ligand. Proc Natl Acad Sci USA 108:768-773.